<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01431222</url>
  </required_header>
  <id_info>
    <org_study_id>IsarClip</org_study_id>
    <nct_id>NCT01431222</nct_id>
  </id_info>
  <brief_title>Abrogation of Mitral Regurgitation Using the MitraClip System in High-Risk Patients Unsuitable for Surgery</brief_title>
  <acronym>ISAR-CLIP</acronym>
  <official_title>Interventional Strategy to Abrogate Mitral Regurgitation Using the MitraClip System in High-Risk Patients Considered Unsuitable for Surgery (ISAR-CLIP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective in this randomized trial is to evaluate the safety and efficacy of a
      MitraClip treatment in symptomatic patients with severe mitral regurgitation in comparison to
      the previous default medical treatment - in a study population who is not amenable for the
      conventional surgical approach as current gold standard.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The presence of a significant mitral regurgitation (MR) seriously effects the patient`s
      quality of life and is associated with an increased mortality rate. The operative treatment
      of MR - either mitral valve repair or replacement - is the current gold standard. However
      mere half of the patients with a severe and symptomatic MR actually undergo an operative
      treatment (EURO-HEART-SURVEY) due to restricted left ventricular ejection fraction, elderly
      patients with co-morbidities and high perioperative morbidity and mortality. In contrast,
      patients with severe and symptomatic MR not suitable for operation are treated with
      palliative medical therapy (heart insufficiency therapy). With the development of the
      MitraClip device - a minimal-invasive, percutaneous catheter-based technique - high-risk
      patients not suitable for surgery may receive a promising alternative treatment by
      approximating the mitral leaflets, thus creating a permanent leaflet coaptation and reducing
      or even abrogating the MR. The current data support the assumption of a safe and effective MR
      reduction with the MitraClip-System in inoperable high-risk patients with severe MR. But the
      feasibility still has to be proven in this special patient population.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of Dyspnoea of at least one class (NYHA-Classification)</measure>
    <time_frame>after 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>composite endpoint and clinical outcome measured by NYHA-classification</measure>
    <time_frame>1 year and 2 years after intervention</time_frame>
    <description>composite endpoint (death of any cause, myocardial infarction, stroke, sepsis, TIMI major bleeding, clip embolisation, partial clip detachement, acute renal failure)
unscheduled hospitalization due to increased heart insuffiecency
changes in quality of life
echocardiographic parameters
loboratory parameters
resiliance measured by spiroergometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>percutaneous treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>optimal medical treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>percutaneous treatment by implanting a Mitra Clip device</intervention_name>
    <description>With a minimal-invasive, percutaneous catheter-based technique and trans-septal approach under transesophageal echocardiographic and fluoroscopic guidance, the MitraClip device grasps and approximates the mitral leaflets thus creating a double-orifice mitral valve with a permanent leaflet coaptation and a reduction or even abrogation of mitral regurgitation.</description>
    <arm_group_label>percutaneous treatment</arm_group_label>
    <arm_group_label>optimal medical treatment</arm_group_label>
    <other_name>Mitra Clip system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age ≥ 18 years

          -  signed written consent

          -  symptomatic patients (NYHA-stadium ≥ III) for at least 3 months with an exploited
             medical heart insufficiency therapy

          -  increased perioperative risk with a logistic EuroScore ≥ 15 or STS-Score ≥ 15

          -  MR grade ≥ 2, amenable for MitraClip intervention assessed by an experienced
             interventional cardiologist

          -  Affirmation of in-operability by a &quot;Heart-Team&quot; consisting of either 1 cardiac surgeon
             and 1 cardiologist or 3 cardiologists

        Exclusion Criteria:

          -  one essential cardiovascular event in the past 6 weeks; i. e. myocardial infarction,
             stroke, shock, cardiac decompensation, or the necessity of catecholamine therapy for
             haemodynamic stabilisation

          -  implantation of a biventricular pacemaker-device for cardiac resynchronisation therapy
             in the past 3 months

          -  solid tumor with a live expectancy &lt; 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joerg Hausleiter, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steffen Massberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juergen Pache, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hasema Lesevic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joerg Hausleiter, MD</last_name>
    <phone>+49-89-1218-0</phone>
    <phone_ext>4018</phone_ext>
    <email>hausleiter@dhm.mhn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hasema Lesevic, MD</last_name>
    <phone>+49-89-1218-0</phone>
    <email>lesevic@dhm.mhn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joerg Hausleiter, MD</last_name>
      <phone>+49-89-1218-0</phone>
      <phone_ext>4018</phone_ext>
      <email>hausleiter@dhm.mhn.de</email>
    </contact>
    <contact_backup>
      <last_name>Hasema Lesevic, MD</last_name>
      <phone>+49-89-1218-0</phone>
      <email>lesevic@dhm.mhn.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2011</study_first_submitted>
  <study_first_submitted_qc>September 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2011</study_first_posted>
  <last_update_submitted>September 8, 2011</last_update_submitted>
  <last_update_submitted_qc>September 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Joerg Hausleiter</name_title>
    <organization>Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum Muenchen</organization>
  </responsible_party>
  <keyword>severe mitral regurgitation</keyword>
  <keyword>interventional mitral valve reconstruction</keyword>
  <keyword>inoperable</keyword>
  <keyword>EuroSCORE</keyword>
  <keyword>STS Risk Score</keyword>
  <keyword>MitraClip</keyword>
  <keyword>fluoroscopy</keyword>
  <keyword>echocardiography</keyword>
  <keyword>percutaneous treatment of mitral regurgitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

